IMMX
NASDAQ · Biotechnology
Immix Biopharma Inc
$9.11
-0.57 (-5.89%)
Financial Highlights (FY 2025)
Revenue
163.82M
Net Income
-44,702,535
Gross Margin
52.2%
Profit Margin
-27.3%
Rev Growth
+3.0%
D/E Ratio
0.40
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 52.2% | 52.2% | 52.2% |
| Operating Margin | -22.4% | -20.5% | -18.5% |
| Profit Margin | -27.3% | -28.3% | -27.5% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 163.82M | 157.27M | 158.27M |
| Gross Profit | 85.55M | 82.13M | 82.66M |
| Operating Income | -36,760,556 | -32,287,784 | -29,253,227 |
| Net Income | -44,702,535 | -44,556,024 | -43,506,106 |
| Gross Margin | 52.2% | 52.2% | 52.2% |
| Operating Margin | -22.4% | -20.5% | -18.5% |
| Profit Margin | -27.3% | -28.3% | -27.5% |
| Rev Growth | +3.0% | +15.0% | +13.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 77.94M | 80.60M | 75.75M |
| Total Equity | 194.03M | 190.62M | 197.05M |
| D/E Ratio | 0.40 | 0.42 | 0.38 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -45,867,623 | -43,115,764 | -48,402,369 |
| Free Cash Flow | -22,695,190 | -23,234,474 | -24,663,069 |